3 results about "Pheochromocytoma" patented technology

This invention proposes a method and culture medium for culturing human pheochromocytoma organoids, belonging to the field of organoid culture technology. The method includes the following steps: S1. Pheochromocytoma treatment; S2. ON-TOP seeding of pheochromocytoma and induction culture; S3. Embedding of pheochromocytoma in a gel and maintenance culture. This method is simple, rapid, and efficient. Due to the characteristics of pheochromocytoma, which grows slowly, the ON-TOP embedding method is required to provide a special growth environment and improve the culture success rate. This invention provides a reliable research tool for studying the development and metabolic mechanisms of pheochromocytoma.

Provided herein are methods and compositions for reducing the expression and / or activity of an oncogenic transfer RNA (tRNA). Composition for treating cancer in the subject are disclosed, comprising an inhibitor of an oncogenic transfer RNA (tRNA) to a subject in need thereof, wherein the oncogenic tRNA comprises an inhibitory nucleic acid such as ARG-TCT-4-1, an siRNA, an shRNA, an miRNA, an antisense oligonucleotide, or a nucleic acid modification such as a locked nucleic acid, a phosphorothioate modification, a 2′—O-methyl modification, a 2′—O-methoxyethyl modification, a 2′-fluoro modification, a phosphorodiamidate modification, or a mesylphosphoramidate modification. The disclosed compositions are disclosed as treating cancers such as a sarcoma, a glioblastoma, an adrenocortical carcinoma, a cholangiocarcinonma, a melanoma, a glioma, a diffuse glioma, a mature B cell neoplasm, a non-small cell lung cancer, an esophagogastric adenocarcinoma, a pheochromocytoma, a hepatocellular carcinoma, an endometrial carcinoma, a pancreatic adenocarcinoma, a breast carcinoma, an invasive breast carcinoma, a head and neck squamous cell carcinoma, a bladder urothelial carcinoma, a colorectal adenocarcinoma, an ovarian epithelial tumor, a prostate adenocarcinoma, a cervical squamous cell carcinoma, a renal non-clear cell carcinoma, or a renal clear cell carcinoma.

The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma / Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).